Sagimet Biosciences Inc. Series A Common Stock (SGMT) Stock Price
SGMTStock
$8.02+6.23%52W
Market Cap$568.69M
P/E—
PEG Ratio—
Div yield—
Beta3.58
SGMT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)34.86%
Price vs S&P 500 (4W)-24.42%
VGM Score70.73
SGMT Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.27 | -$0.26 | +2.13%(+$0.01) | |
| Q1 2026 | -$0.35 | -$0.33 | +5.04%(+$0.02) | |
| Q4 2025 | -$0.40 | -$0.29 | +27.79%(+$0.11) | |
| Q3 2025 | -$0.39 | -$0.40 | -2.24%(-$0.01) | |
| Q2 2025 | -$0.50 | -$0.32 | +35.47%(+$0.18) |
SGMT Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.22
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
SGMTSagimet Biosciences Inc. Series A Common Stock | — | — | B | — | — | — | — | $8.02 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing selective fatty acid synthase (FASN) inhibitors to treat metabolic diseases driven by dysfunctional lipid metabolism. The company's lead candidate, denifanstat, is an oral, once-daily FASN inhibitor in development for nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated liver disease. Sagimet is focused on advancing its proprietary FASN inhibitor platform across multiple indications where lipid dysregulation plays a pathogenic role.